RheumWorld 🌎

Emerging therapies in the Allergy/Immunology world by Dr. Anna Postolova Remiburtinib for Urticaria Depemokimab (twice yearly administration) for eosinophilic asthma @RheumNow #RWCS2026

“A loss of 6 kg of lean body mass (aka muscle) is equivalent to aging 10 years.” - Dr Hsueh #RWCS2026

Pearl: Patients with scurvy can have elevated ESR and CRP. Buzzwords: corkscrew hair, gingivitis, microhemorrhages - Dr S Shenoi #RWCS

RT @@Gibson_RheumPAC Eczematous eruptions with IL-17 inhibition are increasingly recognized. Registry data suggest higher adjusted incidence with IL-17 inhibitors compared with other biologic classes, especially in older patients and those with atopic history. #RNL26

Potential side effects of GLP1, incretins… consider a baseline ophthalm exam. - Dr Hsueh #RWCS26

What is the impact of NSAID intake on radiographic spinal progression in axSpA? Higher NSAID intake, particularly COX-2 inhibitors, appeared to slow radiographic progression, suggesting a potential effect on slowing structural damage A&R doi.org/10.1002/art.43…

🦴 Hip AxSpA ≠ Hip OA — read the X-ray smartly 🔹 Joint space: OA → superolateral | AxSpA → concentric (🚩) 🔹 Bone: OA → marginal osteophytes | AxSpA → head–neck collar + fluffy enthesopathy 🔹 Laterality: OA uni/bi | AxSpA usually bilateral 🔹 Ankylosis: Rare in OA | Seen in AxSpA 🔹 Entheses: OA spared | AxSpA erosions + irregular new bone ⚠️ Why it matters: Hip AxSpA = earlier onset, faster damage, ↑ THA risk, worse prognosis 📉 Structural progression may continue despite symptom control. 🧠 MRI adds power: detects BME, synovitis & erosions before X-ray; predicts treatment response. 📚 Key DOIs • Hip involvement in axSpA – 10.3389/fimmu.2021.697770 • Entheseal radiographic lesions in r-axSpA (2025) – 10.1007/s10067-025-07345-8 • Advanced imaging in SpA (2025 review) – 10.1016/j.berh.2025.102064 👉 Concentric JSN + bilateral disease + enthesopathy = think AxSpA, not OA. #AxSpA #HipArthritis #Rheumatology #MSKImaging #Radiology #OA #Enthesitis #RheumTwitter #MedEd

Dr Cockerell on cutaneous vasculitis. Clinicians and pathologists are often not speaking the same language. This can lead to both under and over diagnosis. #RNL26 @RheumNow

Update of 2025 ASAS-SPARTAN Revised Classification Criteria for AxSpA @RheumNow #RNL26 Notes must exclude mimics MRI findings involve active & structural lesions, not just bone marrow edema Difficult to meet clinically without any imaging criteria (xray or MRI) Pub pending

Radiographic differences b/t OA vs AxSpA on hip imaging #RNL26

Kicking off #RNL26! Great talk by Dr. Demoruelle on mucosal origins of RA Environment + Predisposition --> Autoimmunity Top 3 sites? Lung, gut, mouth Perhaps a target to prevent RA in the future?

Gout Rx timeline. Dr Terkeltaub #RNL26

I mean , thank for this GOAT slide. METHOTREXATE is not Infamous. Its kind and good when its used properly with proper monitoring ⁦@jeffsparks⁩ #RNL2026 ⁦@RheumNow⁩

Dr Cockerell discusses the wide range of causes of leucocytoclastic vasculitis #RNL26 @RheumNow

Great talk by ⁦@jeffsparks⁩ on RA- ILD #RNL2026 ⁦@RheumNow⁩

Myositis antibodies phenotype can direct how extensive cancer screening in IIM. ⁦@docrota⁩ ⁦@RheumNow⁩ #RNL26

How to manage IL17i induced eczema? Dr Merola has a few suggestions… #RNL26

I really dislike ESSDAI as an outcome measure, ESSPRI makes way more sense Covers dryness, fatigue, and pain - aka "what matters most to most patients with Sjogrens" Neither baseline nor change in ESSDAI & ESSPRI correlate with each other (r=0.20 & r = 0.14!) #RNL26

Data shows intraarticular joint injx within 6 months of surgery increases risk for infection. -Dr S Goodman #RNL26

Will print this pure gold slide , to all my gout patients, inflammation is not benign and its linked to cardiovascular and MACE. Please take your pills. Dr. Tarekeltaub ⁦@RheumNow⁩ #RNL2026